Pregabalin 25 / 75 / 150 Biotech 25 / 75 / 150 Capsules, hard.
PDF Leaflet Revision Date: 06 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of neuropathic pain due to Herpes zoster infections and diabetes.
Dosage (summary)
Starting dose: 75 mg twice daily; may increase to 150 mg twice daily after 3-7 days.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding not advised.
Key Drug Interactions
- CNS depressants
- Opioids
Contraindications
- Hypersensitivity to pregabalin or excipients
Common side effects
- Dizziness
- Somnolence
- Increased appetite
Counselling Points
- Avoid driving until effects are known
- Monitor for signs of misuse or dependence
- Gradual discontinuation recommended
Serious warnings
- Risk of respiratory depression
- Suicidal ideation
- Withdrawal symptoms
Important Disclaimer
The Pregabalin 25 / 75 / 150 Biotech 25 / 75 / 150 Capsules, hard. professional information leaflet below is the property of Biotech Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
